We report that MMR-deficient cells retain sensitivity to brostallicin, thereby extending the list of potential anticancer agents for use in the treatment of MMR-deficient tumours, and that brostallicin-induced cytotoxicity may not require ATM and DNA-PK. This evidence concerns the gene ATM and neoplasm.